Drug profile · INN
methylphenidate
ATENZA (SPAIN)
methylphenidate (ATENZA (SPAIN)) is a norepinephrine transporter inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — methylphenidate
- US status
- approved
- Class
- —
- Route
- TRANSDERMAL
- Patents
- 1
- Programs
- 11
- Data quality
- 0.84
Quick answer
methylphenidate (ATENZA (SPAIN)) is a norepinephrine transporter inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Norepinephrine transporter inhibitor
Primary target: Sodium-dependent dopamine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is methylphenidate?
methylphenidate (ATENZA (SPAIN)) is a norepinephrine transporter inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for methylphenidate?
ATENZA (SPAIN) is a marketed brand name for methylphenidate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methylphenidate?
methylphenidate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.